Buy Semaglutide Online: Brand vs Compounded Forms

This page compares the brand drugs with compounded semaglutide and then covers the part of the market FDA warns about most: fake and mislabeled products. Some links on this page are affiliate links, and we may earn a commission if you use them. Every status below carries its source and date, and where a fact could not be confirmed we say so.

• FDA status

  Wegovy, Ozempic and Rybelsus are FDA-approved brand drugs. Compounded semaglutide is not FDA-approved.

• Lawful route

  A prescriber's order, then a US pharmacy that holds a license in your state

• Brand or compounded

  Both are sold. Novo Nordisk makes the brands; 503A pharmacies and 503B outsourcing facilities make compounded versions.

• Whoosh offers this

  Yes, in compounded form, according to Whoosh (read 2026-10-07)

As of 2026-10-07; each source appears under Sources.

The approved brand drugs

Three brand products contain semaglutide, and each has its own label on DailyMed. The indications below come from those labels.

As of 2026-10-07. Wegovy's label says it is used with a reduced-calorie diet and more physical activity.

All three labels carry a boxed warning under the heading "WARNING: RISK OF THYROID C-CELL TUMORS." The labels say semaglutide caused thyroid C-cell tumors in rodents and that it is unknown whether it does so in humans. The labels bar use by anyone with medullary thyroid carcinoma in their own or their family's history, or with Multiple Endocrine Neoplasia syndrome type 2. The labels call routine calcitonin monitoring or thyroid ultrasound "of uncertain value" for early detection.

Manufacturer self-pay, as the manufacturer states it

Novo Nordisk sells Wegovy directly. Its NovoCare page, read 2026-10-07, lists a Wegovy pill from $149 a month at the lowest tier and the Wegovy pen at $349 a month at standard tiers, with an introductory price for new pen patients' first two monthly fills through 2026-12-31. It prints a list price of $1,349.02 per package, says eligibility and restrictions apply and states that Novo Nordisk may modify or cancel the program at any time. The page also describes NovoCare Pharmacy for delivery or pickup and links to resources for finding a doctor you can meet virtually. Read any figure as a snapshot and read the live page.

Salt forms and counterfeits

This is where the buying decision gets risky, and where FDA has been most direct. FDA's page on unapproved GLP-1 drugs, current as of 2026-10-01, makes four separate statements.

Salt forms. Some products are sold as semaglutide sodium or semaglutide acetate. FDA states these "are different active ingredients" from the semaglutide in the approved drugs, and that it is "not aware of any lawful basis for their use in compounding." If a product's ingredient list says sodium or acetate, that is a question for the pharmacy, in writing.

Counterfeits. FDA states that counterfeit Ozempic is marketed in the United States. FDA also reports that it has issued warning letters over illegally marketed semaglutide and urges consumers to buy only from state-licensed pharmacies.

Pharmacies that do not exist. FDA says that in some cases the compounding pharmacies named on labels "do not exist," and in others the label carries the name of a real licensed pharmacy that did not make the product. FDA describes one adverse event report involving a product labeled as compounded from a pharmacy that had not compounded it.

Research labels. FDA has warned companies that sell semaglutide labeled "for research purposes" or "not for human consumption" directly to consumers with dosing instructions, and urges consumers not to purchase those products. Our page on research peptides explains why the label does not change what a product is meant for.

Red flags, with sources

• A pharmacy name you cannot find. FDA says named pharmacies on some labels do not exist. Look the license up in the state board of pharmacy database. (FDA, 2026-10-01)
• No prescriber involved. FDA lists a service that does not require screening and a prescription by a licensed doctor as a red flag. (FDA, 2026-10-01)
• Sameness pitch. Telling you a compounded drug matches the approved one is on FDA's list. (FDA, 2026-10-01)
• Medicine that looks different. A product that looks unlike what you were given before, a damaged box, typos on the label or a mismatched pharmacy address are flags. (FDA, 2026-10-01)
• Deep discounts. Prices that seem too good to be true are on the same list. (FDA, 2026-10-01)

Compounded semaglutide and what FDA says

FDA states "compounded drugs are not FDA approved." It also says a compounded drug might be appropriate when a patient's medical need cannot be met by an approved drug or the approved drug is not commercially available.

• Shortage status. FDA recorded the semaglutide shortage as resolved on 2025-02-21. Its enforcement-discretion periods ended on 2025-04-22 for 503A pharmacies, or later per the court, and ran to 2025-05-22 for outsourcing facilities. A federal court denied the preliminary injunction on 2025-04-24.
• "Essentially a copy." FDA's page, current as of 2026-04-01, says a 503A pharmacy may not regularly compound drugs that are essentially copies of an approved product, and that a semaglutide-plus-B12 product may be considered one.
• Bulks list. The same page says semaglutide does not currently appear on the 503B bulks list or on FDA's drug shortage list. FDA proposed on 2026-04-30 to exclude semaglutide, tirzepatide and liraglutide from that list. Comments were accepted until 2026-07-30 after an extension. Our search found no final action by 2026-10-07, so it remains a proposal.
• Adverse events. FDA reports 990 adverse event reports for compounded semaglutide as of 2026-05-31, and says pharmacies that are not outsourcing facilities are not required to submit them, so reports are likely undercounted.
• Dosing errors. FDA's alert dated 2024-07-26 describes patients drawing up five to 20 times more than intended from multi-dose vials, and confusion among mL, mg and units. FDA says the approved injectable semaglutide products, as of that date, were single pens with standard concentrations. We give no dose figures.

Our tirzepatide page covers the sibling drug, and compounded peptides explains 503A and 503B in plain words.

What Whoosh states it offers

Whoosh says on its product page (read 2026-10-07) that it provides compounded semaglutide as a microdose injection and a full-dose injection. Each online intake goes to a licensed physician for review, and any prescription is filled by a 503A or 503B pharmacy that Whoosh describes as licensed and US-based. Compounded medications are not FDA-approved, and Whoosh's own disclaimer says so. Whoosh also states that finishing intake does not guarantee a prescription. Where its pages contradict each other, our Whoosh Wellness review lists the conflicts.

Start the Whoosh intake ↗

A licensed physician decides whether a prescription is appropriate, so there is no promise of approval.

Questions to ask before you pay

1. Are you being sold the brand drug or a compounded one, and who made it?
2. What is the active ingredient on the label? If it says sodium or acetate, why?
3. Which pharmacy fills it, and is its license listed with my state board of pharmacy?
4. Who is the prescriber, and how do I reach them after the product arrives?
5. What is the written price, what renews automatically and how do I cancel?
6. How do the boxed-warning risks apply to my history?

Sources

• DailyMed: Wegovy label label effective 2026-06-18, read 2026-10-07
• DailyMed: Ozempic label label effective 2026-06-01, read 2026-10-07
• DailyMed: Rybelsus label label effective 2026-01-30, read 2026-10-07
• FDA: Concerns with unapproved GLP-1 drugs page current as of 2026-10-01, read 2026-10-07
• FDA: Policies for compounders as GLP-1 supply stabilizes page current as of 2026-04-01, read 2026-10-07
• FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list dated 2026-04-30, read 2026-10-07
• Federal Register: 2026-12937 (comment period extended) published 2026-06-26, read 2026-10-07
• FDA: Alert on dosing errors with compounded semaglutide page dated 2024-07-26, read 2026-10-07
• NovoCare: Wegovy page as stated by the manufacturer, read 2026-10-07
• Whoosh Wellness: semaglutide product page as stated by Whoosh, read 2026-10-07

FAQ

Not medical advice. See the medical disclaimer.